Court sides with Sandoz in Amgen biosimilar case

The U.S. District Court for the Northern District of California denied motions made by Amgen Inc. (NASDAQ:AMGN) against the Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) that would have delayed sales of Zarxio filgrastim-sndz, Sandoz's biosimilar of Neupogen filgrastim (see BioCentury Extra, March 13).

Amgen said it will appeal the decisions. Sandoz said the companies had previously agreed to jointly request an expedited review of any appeal, "given the importance of the case to future biosimilars." ...